126 results about "Gamma-Tocopherol" patented technology

The present invention is generally related to the discovery of the therapeutic benefit of administering gamma-tocopherol and gamma-tocopherol derivatives. More specifically, the use of gamma-tocopherol and racemic LLU-alpha, (S)-LLU-alpha, or gamma-tocopherol derivatives as antioxidants and nitrogen oxide scavengers which treat and prevent high blood pressure, thromboembolic disease, cardiovascular disease, cancer, natriuretic disease, the formation of neuropathological lesions, and a reduced immune system response are disclosed.

The present invention involves the use of desmethyl tocopherols such as gamma tocopherol for the protection of cardiovascular tissue from nitrative stress. While mechanisms other than scavenging of reactive nitrogen species may be involved, desmethyl tocopherols exhibit significant protection and may be utilized to treat or help prevent cardiovascular particularly arterial vascular disease. The desmethyl tocopherols may be administered dietarily or parenterally when a more direct dosage is desired. Both routes may be utilized together or separately to optimize therapeutic and prophylactic benefits. The lessening of damage induced by reactive nitrogen species leads to the lessening of arterial blockage in thrombosis.

The present invention relates to compositions comprising DHA, EPA, LA and GLA. The compositions may further comprise other omega-3 PUFAs, MUFAs, SFAs, gamma tocopherol, Vitamin A and Vitamin B. The compositions are useful for treating neurologic disorders. The compositions are administered chronically for the prevention and/or treatment of multiple sclerosis (MS) and other degenerative diseases.

Disclosed herein is a method of preventing or retarding the progression of diabetic microvascular and macrovascular complications by chronically administering a therapeutically effective amount of gamma-tocopherol to a diabetic patient. It is further disclosed that a greater cytoprotective benefit is provided by administering a blend of gamma-tocotrienol and alpha-tocotrienol.

The invention relates to a method for separating single tocopherol from mixed tocopherol, which takes the mixed tocopherol with a content of 50 percent to 100 percent as a raw material and adopts a four-area simulated moving bed chromatography system to separate a d-alpha-tocopherol, a d-beta-tocopherol, a d-gamma-tocopherol and a d-delta tocopherol with the purity and yield all more than 98 percent. As the simulated moving bed chromatography separation is a continuous process, the method has the advantages of high degree of production automation, simple technique, high production efficiency, continuous production and stable product quality. As an adsorbent and a solvent have low consumption, the whole separating device does not relate to chemical reactions.

A novel method for improving the tissue quality of an animal is provided. The method comprises feeding the animal a diet supplemented with gamma-tocopherol in an amount effective to improve the tissue quality. The gamma-tocopherol may be fed alone or in combination with other antioxidants, such as alpha-tocopherol. The method may be practiced on ruminants and non-ruminants.

Disclosed is a process for the production of high purity alpha-tocotrienol from palm oil extract. More particularly, the invention relates to a process for the separation of alpha-tocotrienol from a mixtures of other tocotrienols and tocopherols and the use of a simplified separation scheme based on a combination of solid phase extraction and simulated moving bed (SMB) separation steps employing polar phase simulated moving bed operation. The process is useful for providing a continuous route and a simplified processing route to providing pure alpha-tocotrienol as a major product essentially free of other tocotrienols and tocopherols including: beta-tocopherol, gamma-tocotrienol, delta-tocotrienol, gamma-tocopherol, delta-tocopherol, front end and back end carotenoids, and alpha-tocopherol as a by-product from palm oil extract. Alpha-tocotrienol is a form of vitamin E and may be useful as a treatment for preventing stroke or reducing brain and nerve damage following a stroke.

A stent is provided in combination with delivery of a tocopherol agent, and in particular a des-methyl tocopherol agent, and further beneficially a gamma-tocopherol agent, so as to reduce restenosis along the vessel or other lumenal wall where the stent is implanted. In particular applications, the stent is an endolumenal stent, and more specific beneficial applications is an endovascular stent, and the gamma-tocopherol elutes from a coating or carrier coupled with the stent. Certain combinations are provided with the des-methyl-tocopherol or phytyl substituted chromanol, e.g. gamma-tocopherol, combined with an additional agent such as an anti-restenosis agent, e.g. sirolimus, tacrolimus, everolimus, or paclitaxel, in order to provide synergistic benefit to tissues along the stented or recanalized regions. Other forms of tocopherol or tocotrienol, or other phytyl substituted chromanols, and other compounds such as palm oil, are also contemplated, for use to treat restenosis.

The invention discloses a method for preparing natural alpha tocopherol and mixing tocopherol by a one-step method, which relates to the technical field of separation and extraction in bioengineering. The method comprises the following steps: performing esterification of plant oil deodorizer distillate; washing; dissolving and filtering tocopherol; adsorbing a fluidized bed of a tocopherol solution by resin; dynamically absorbing a tocopherol adsorption waste liquid by resin; desorpting, and performing molecular distillation to obtain the alpha tocopherol and mixing tocopherol. According to the invention, no organic solvent is used for the alpha tocopherol, and alpha tocopherol has the advantages of environmental protection and safety, and has the characteristics of green and health by comparing with the alpha tocopherol prepared by a traditional method; and the produced mixing tocopherol has the characteristics of high quality, high yield, low cost, and easy batch production.

The invention discloses a kit for bisulfite conversion of free DNA. The kit comprises a bisulfite solution, a protective solution, washing liquor A, a magnetic bead suspension, washing liquor B, washing liquor C and eluate, wherein the protective solution is prepared from the following ingredients: 80% to 85% of tetrahydrofuran furfuryl alcohol, 10% to 15% of D-alpha tocopherol cetomacrogol 1000 succinate, 0.2% to 0.3% of tetrahydroglycosyl acetate, 0.05% to 0.1% of ethoxychrysoidine and the balance of water. The invention further provides a method for bisulfite conversion and DNA purificationof the free DNA by using the kit. According to the kit, a sulfite conversion method is subjected to great technological improvement, so that ctDNA conversion can be completed rapidly (40 to 60 minutes) under mild conditions (70 DEG C to 80 DEG C), pH of a system can be stabilized, ctDNA degradation is prevented, high-conversion-ratio, high-quality and high-purity free DNA can be rapidly obtained,and full automated operation of methylation researches is facilitated.

A therapy for decreasing the rate of demyelination in multiple sclerosis comprising administering gamma-tocopherol and/or gamma-tocotrienol in a therapeutically effective dosage. The therapeutic dosage is high, between about 800 mg to about 10 grams of gamma-tocopherol and between about 50 mg to about 5 grams of gamma-tocotrienol per day.

The present invention relates to a skin preparation for external application, comprising a tocopherol aminoalkylcarboxylate ester having no substituent on the N atom and/or a salt thereof. Preferable tocopherol aminoalkylcarboxylate in the present invention is one or more compound selected from α-tocopherol derivatives, β-tocopherol derivatives, γ-tocopherol derivatives and δ-tocopherol derivatives. The present invention also relates to a cosmetic material comprising the skin preparation.

This invention relates to methods to reduce or lipid peroxidation and diminish free radical damage in a human, resulting in reduced blood levels of dityrosine, isoprostane, and placental growth factor thus preferably preventing or reducing cardiovascular disease by the in humans administration of compositions comprised of sesame lignans and ‘gamma tocopherol to humans.

The present invention discloses a vehicle rubber sealing strip, which comprises, by weight, an ethylene-propylene-diene monomer, paraffin oil, calcium carbonate, talc powder, a dispersant, an anti-ultraviolet agent, an antioxidant, an anti-scorching agent CTP, a foaming agent, a nitrogen-free vulcanizing agent, an auxiliary vulcanizing agent, a terpene resin, zinc borate powder, phosphate, and alpha-tocopherol. The low-harm and toxicity-free vehicle sealing strip has characteristics of environmental pollution reducing and reasonable cost maintaining.

The invention discloses a decoloration-resistant lipstick sealer. The lipstick sealer is prepared from the following ingredients in parts by weight: 0.5-6 parts of polydimethylsiloxane and polydimethylsiloxane/vinyl polydimethylsiloxane crosslinking copolymer, 5-15 parts of polydimethylsiloxane, 60-70 parts of spherical silicon resin powder, 2-3 parts of jojoba oil, 1-3 parts of shea butter and 0.1-1 part of tocopherol. The product can be smeared on lipstick coated on lips, and forms a layer of protection film to separate the lipstick from external environment, so that the lipstick is effectively prevented from sticking a cup and decoloration; consumers do not need to frequently fix make-up, so that the waste of time is avoided, and the embarrassed situation caused by problems such as cupsticking is avoided; the lipstick sealer is convenient and efficient to use, moderate in price, and suitable for popularization and application; when smeared on the lips, the lipstick sealer feels smooth, fresh and cool, has very good moistening and moisturizing effects, and can increase moisture of lip skin and prevent the lips from drying and chapping, thereby further recovering and maintainingthe natural resilience of the lips.

The invention relates to a preparation method of mitochondria-targeted tocopherol-oleanolic acid double-drug nanoparticles. The bioavailability and the targeting property of the medicine can be effectively improved. The technical scheme is as follows: the preparation method comprises the following steps of: respectively dissolving an anti-cancer drug, a targeting carrier, lecithin and cholesterolin an organic solvent until the materials are totally dissolved, mixing the dissolved solutions together, carrying out rotary evaporation to remove the organic solvent to obtain a film formed on the wall, drying the film in a vacuum drying oven, thoroughly removing the organic solvent, adding a hydration solvent, magnetically stirring the hydrated product, carrying out ultrasonic treatment, sequentially passing through polycarbonate films with different pore diameters, and carrying out extrusion crushing to obtain the mitochondria-targeted tocopherol-oleanolic acid double-drug nanoparticles. According to the nanoparticle, triphenylphosphine connected to tocopherol is utilized, positive charges carried by triphenylphosphine are easily enriched in mitochondria, so that the effect of mitochondria targeted drug delivery is achieved, and the nanoparticle is an innovation on mitochondria targeted preparations of nanoparticles.